



Phone: (785) 296-4056 Fax: (785) 296-8420 pharmacy@ks.gov www.pharmacy.ks.gov

Alexandra Blasi, Executive Secretary

Laura Kelly, Governor

Testimony concerning HB 2218 House Committee on Health and Human Services Presented by Alexandra Blasi February 11, 2025

Chairman Carpenter and Members of the Committee:

The Kansas State Board of Pharmacy respectfully submits this neutral testimony on HB 2218. As the agency responsible for recommending updates to and regulating under the Kansas Uniform Controlled Substances Act, the Board appreciates that the maker of the bill communicated with the Board in advance of bringing these amendments. There is precedence in Kansas for the pre-scheduling of a drug in advance of receiving FDA approval. A very similar process was followed by the Kansas Legislature in 2018 with the drug Epidiolex (active ingredient cannabidiol).

The Board had an opportunity to preview HB 2218 and has no concerns.

Respectfully submitted.